Online inquiry

IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8127MR)

This product GTTS-WQ8127MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8127MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5575MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ2670MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ14752MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ14575MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ10936MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ11824MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ9026MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ9854MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW